NASDAQ:ATRA Atara Biotherapeutics - ATRA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.80 -0.18 (-6.04%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.76▼$3.0450-Day Range$2.83▼$5.4652-Week Range$2.66▼$10.01Volume936,528 shsAverage Volume1.18 million shsMarket Capitalization$268.60 millionP/E RatioN/ADividend YieldN/APrice Target$14.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Atara Biotherapeutics MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside587.5% Upside$19.25 Price TargetShort InterestBearish17.41% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.41Based on 3 Articles This WeekInsider TradingSelling Shares$129,165 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.17) to ($1.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector808th out of 1,009 stocksBiological Products, Except Diagnostic Industry139th out of 166 stocks 3.1 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.25, Atara Biotherapeutics has a forecasted upside of 587.5% from its current price of $2.80.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.41% of the outstanding shares of Atara Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Atara Biotherapeutics has recently increased by 18.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtara Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atara Biotherapeutics is -0.87. Previous Next 1.9 News and Social Media Coverage News SentimentAtara Biotherapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atara Biotherapeutics this week, compared to 2 articles on an average week.Search InterestOnly 39 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $129,165.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Atara Biotherapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($2.17) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtara Biotherapeutics has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Atara Biotherapeutics (NASDAQ:ATRA) StockAtara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.Read More Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comAtara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 21, 2023 | americanbankingnews.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Hold" by BrokeragesMarch 30, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 3, 2023 | finance.yahoo.comAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2023 | finance.yahoo.comAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care ConferenceFebruary 21, 2023 | finance.yahoo.comAtara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual ConferenceFebruary 15, 2023 | finance.yahoo.comThe past five years for Atara Biotherapeutics (NASDAQ:ATRA) investors has not been profitableFebruary 10, 2023 | msn.comLooking Into Atara Biotherapeutics's Return On Capital EmployedMarch 30, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 8, 2023 | finance.yahoo.comAtara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue EstimatesFebruary 8, 2023 | finance.yahoo.comAtara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational ProgressFebruary 8, 2023 | finance.yahoo.comPierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)February 6, 2023 | finance.yahoo.comAtara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023January 4, 2023 | finance.yahoo.comAtara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2023 | finance.yahoo.comAtara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 20, 2022 | marketwatch.comAtara Biotherapeutics Gets $31M Royalty Interest Financing Deal, Shares Rise 6%December 20, 2022 | finance.yahoo.comAtara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare RoyaltyDecember 19, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Madrigal Pharmaceuticals (MDGL) and Atara Biotherapeutics (ATRA)December 19, 2022 | benzinga.comAtara Biotherapeutics' Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDDecember 19, 2022 | markets.businessinsider.comAtara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLDDecember 19, 2022 | finance.yahoo.comAtara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDDecember 19, 2022 | finance.yahoo.comAtara Biotherapeutics Announces Changes to Its Board of DirectorsDecember 17, 2022 | seekingalpha.comConsider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.December 12, 2022 | finance.yahoo.comAtara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual MeetingNovember 23, 2022 | finance.yahoo.comAtara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx ConferenceNovember 22, 2022 | finance.yahoo.comNewsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue ForecastsNovember 10, 2022 | finance.yahoo.comAtara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In LineSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Company Calendar Last Earnings2/08/2023Today3/30/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATRA CUSIPN/A CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees578Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.25 High Stock Price Forecast$50.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+430.6%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-228,300,000.00 Net Margins-359.12% Pretax Margin-359.10% Return on Equity-140.05% Return on Assets-70.60% Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.72 Sales & Book Value Annual Sales$63.57 million Price / Sales4.23 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book2.11Miscellaneous Outstanding Shares95,930,000Free Float92,090,000Market Cap$268.60 million OptionableOptionable Beta0.99 Key ExecutivesPascal TouchonPresident, Chief Executive Officer & DirectorUtpal KoppikarChief Financial Officer & Senior Vice PresidentManher AJ JoshiChief Medical OfficerJakob DupontGlobal Head-Research & DevelopmentAnhco NguyenChief Scientific OfficerKey CompetitorsSangamo TherapeuticsNASDAQ:SGMOJATT AcquisitionNYSE:JATTPoseida TherapeuticsNASDAQ:PSTXVectivBioNASDAQ:VECTSutro BiopharmaNASDAQ:STROView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 11,217 shares on 3/23/2023Ownership: 0.038%Pascal TouchonSold 15,679 sharesTotal: $56,914.77 ($3.63/share)Jakob DupontSold 5,074 sharesTotal: $18,418.62 ($3.63/share)Amar MuruganSold 4,221 sharesTotal: $15,322.23 ($3.63/share)Utpal KoppikarSold 6,871 sharesTotal: $24,941.73 ($3.63/share)View All Insider TransactionsView All Institutional Transactions ATRA Stock - Frequently Asked Questions Should I buy or sell Atara Biotherapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares. View ATRA analyst ratings or view top-rated stocks. What is Atara Biotherapeutics' stock price forecast for 2023? 7 brokerages have issued 12 month price objectives for Atara Biotherapeutics' shares. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they predict the company's share price to reach $19.25 in the next twelve months. This suggests a possible upside of 587.5% from the stock's current price. View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts. How have ATRA shares performed in 2023? Atara Biotherapeutics' stock was trading at $3.28 at the start of the year. Since then, ATRA stock has decreased by 14.6% and is now trading at $2.80. View the best growth stocks for 2023 here. Are investors shorting Atara Biotherapeutics? Atara Biotherapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 16,700,000 shares, an increase of 18.7% from the February 28th total of 14,070,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is currently 13.1 days. View Atara Biotherapeutics' Short Interest. When is Atara Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ATRA earnings forecast. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings data on Wednesday, February, 8th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.11. The biotechnology company earned $0.22 million during the quarter, compared to analyst estimates of $60 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 140.05% and a negative net margin of 359.12%. What ETFs hold Atara Biotherapeutics' stock? ETFs with the largest weight of Atara Biotherapeutics (NASDAQ:ATRA) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and iShares Biotechnology ETF (IBB). What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO? 38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE). What is Atara Biotherapeutics' stock symbol? Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA." Who are Atara Biotherapeutics' major shareholders? Atara Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (7.82%), Maverick Capital Ltd. (6.56%), Morgan Stanley (2.80%), Geode Capital Management LLC (1.92%), Citigroup Inc. (1.08%) and Dimensional Fund Advisors LP (0.94%). Insiders that own company stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar. View institutional ownership trends. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Atara Biotherapeutics' stock price today? One share of ATRA stock can currently be purchased for approximately $2.80. How much money does Atara Biotherapeutics make? Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $268.60 million and generates $63.57 million in revenue each year. The biotechnology company earns $-228,300,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. How many employees does Atara Biotherapeutics have? The company employs 578 workers across the globe. How can I contact Atara Biotherapeutics? Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (805) 623-4211 or via email at ehyllengren@atarabio.com. This page (NASDAQ:ATRA) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.